170 related articles for article (PubMed ID: 12782586)
21. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
Kato H; Yoshikawa M; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Tsukada K; Kuwano H
Anticancer Res; 2002; 22(6C):3977-84. PubMed ID: 12553021
[TBL] [Abstract][Full Text] [Related]
22. Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities.
Koyanagi S; Tanigawa N; Nakagawa H; Soeda S; Shimeno H
Biochem Pharmacol; 2003 Jan; 65(2):173-9. PubMed ID: 12504793
[TBL] [Abstract][Full Text] [Related]
23. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence.
Saleh M; Stacker SA; Wilks AF
Cancer Res; 1996 Jan; 56(2):393-401. PubMed ID: 8542597
[TBL] [Abstract][Full Text] [Related]
25. Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro.
Hamsa TP; Kuttan G
Eur J Pharmacol; 2010 Dec; 649(1-3):64-73. PubMed ID: 20858484
[TBL] [Abstract][Full Text] [Related]
26. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
27. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
[TBL] [Abstract][Full Text] [Related]
28. Cytochalasin E, an epoxide containing Aspergillus-derived fungal metabolite, inhibits angiogenesis and tumor growth.
Udagawa T; Yuan J; Panigrahy D; Chang YH; Shah J; D'Amato RJ
J Pharmacol Exp Ther; 2000 Aug; 294(2):421-7. PubMed ID: 10900214
[TBL] [Abstract][Full Text] [Related]
29. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
30. Establishment of a quantitative mouse dorsal air sac model and its application to evaluate a new angiogenesis inhibitor.
Funahashi Y; Wakabayashi T; Semba T; Sonoda J; Kitoh K; Yoshimatsu K
Oncol Res; 1999; 11(7):319-29. PubMed ID: 10757446
[TBL] [Abstract][Full Text] [Related]
31. A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines.
Chong TW; Horwitz LD; Moore JW; Sowter HM; Harris AL
Cancer Res; 2002 Dec; 62(23):6924-7. PubMed ID: 12460908
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
[TBL] [Abstract][Full Text] [Related]
33. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
34. MMAC/PTEN tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer.
Koul D; Shen R; Garyali A; Ke LD; Liu TJ; Yung WK
Int J Oncol; 2002 Sep; 21(3):469-75. PubMed ID: 12168088
[TBL] [Abstract][Full Text] [Related]
35. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.
Gerber HP; Kowalski J; Sherman D; Eberhard DA; Ferrara N
Cancer Res; 2000 Nov; 60(22):6253-8. PubMed ID: 11103779
[TBL] [Abstract][Full Text] [Related]
36. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice.
Reynolds AR; Reynolds LE; Nagel TE; Lively JC; Robinson SD; Hicklin DJ; Bodary SC; Hodivala-Dilke KM
Cancer Res; 2004 Dec; 64(23):8643-50. PubMed ID: 15574772
[TBL] [Abstract][Full Text] [Related]
37. TNP-470 inhibits growth and the production of vascular endothelial growth factor of uterine carcinosarcoma cells in vitro.
Emoto M; Ishiguro M; Iwasaki H; Kikuchi M; Kawarabayashi T
Anticancer Res; 2000; 20(1C):601-4. PubMed ID: 10769702
[TBL] [Abstract][Full Text] [Related]
38. Beta-elemene inhibits melanoma growth and metastasis via suppressing vascular endothelial growth factor-mediated angiogenesis.
Chen W; Lu Y; Wu J; Gao M; Wang A; Xu B
Cancer Chemother Pharmacol; 2011 Apr; 67(4):799-808. PubMed ID: 20563582
[TBL] [Abstract][Full Text] [Related]
39. A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors.
Shimamura M; Nagasawa H; Ashino H; Yamamoto Y; Hazato T; Uto Y; Hori H; Inayama S
Br J Cancer; 2003 Jan; 88(2):307-13. PubMed ID: 12610518
[TBL] [Abstract][Full Text] [Related]
40. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis.
Giavazzi R; Sennino B; Coltrini D; Garofalo A; Dossi R; Ronca R; Tosatti MP; Presta M
Am J Pathol; 2003 Jun; 162(6):1913-26. PubMed ID: 12759248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
